Version vom 27. April 2021, 17:24 Uhr
| 32437749 2020. Human Intestinal Defensin 5 Inhibits SARS-CoV-2 Invasion by Cloaking ACE2.
|
| C7151553 2020. COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles? heel conserved region to minimize probability of escape mutations and drug resistance
|
32286790 ä. Computational Design of ACE2-Based Peptide Inhibitors of SARS-CoV-2
32455942 2020. Potential Therapeutic Targeting of Coronavirus Spike Glycoprotein Priming.
32527713 2020. In Silico computational screening of Kabasura Kudineer - Official Siddha Formulation and JACOM against SARS-CoV-2 spike protein.
32231345 2020. Inhibition of SARS-CoV-2 infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
32354636 ä. Blockade of SARS-CoV-2 infection by recombinant soluble ACE2
32332922 ä. SARS-CoV-2 infection of kidney organoids prevented with soluble human ACE2
32294562 ä. A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease
32359080 2020. Off-target ACE2 ligands: Possible therapeutic option for CoVid-19?
32167153 2020. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?
32373991 2020. In silico screening of natural compounds against COVID-19 by targeting Mpro and ACE2 using molecular docking
32232976 2020. CD-sACE2 inclusion compounds: An effective treatment for coronavirus disease 2019 (COVID-19)
32362217 2020. In silico study the inhibition of angiotensin converting enzyme 2 receptor of COVID-19 by Ammoides verticillata components harvested from Western Algeria
32345124 2020. An in-silico evaluation of different Saikosaponins for their potency against SARS-CoV-2 using NSP15 and fusion spike glycoprotein as targets
32379346 2020. ACE2 Activators for the Treatment of Covid 19 Patients
32332765 2020. Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig
32376627 2020. Design of potent membrane fusion inhibitors against SARS-CoV-2, an emerging coronavirus with high fusogenic activity
32380200 ä. In Silico Design of Antiviral Peptides Targeting the Spike Protein of SARS-CoV-2
| C7197610 ä. Isolation of a human monoclonal antibody specific for the receptor binding domain of SARS-CoV-2 using a competitive phage biopanning strategy
|
| 32231345 ä. Inhibition of SARS-CoV-2 infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
|
Here we generated a series of lipopeptides derived from EK1 and found that EK1C4 was the most potent fusion inhibitor against SARS-CoV-2 S protein-mediated membrane fusion and pseudovirus infection
32336762 2012. Design of Angiotensin?converting Enzyme 2 (ACE2) Inhibitors by Virtual Lead Optimization and Screening
32380200 2020. In silico design of antiviral peptides targeting the spike protein of SARS-CoV-2
32065055 2020. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody
32285293 ä. Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV
32313207 ä. Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor
32451080 ä. A possible strategy to fight COVID-19: Interfering with spike glycoprotein trimerization
32423095 2020. The Expression and Polymorphism of Entry Machinery for COVID-19 in Human: Juxtaposing Population Groups, Gender, and Different Tissues.
32403995 2020. Development of multi-specific humanized llama antibodies blocking SARS-CoV-2/ACE2 interaction with high affinity and avidity.
32592145 2020. Identification of a Potential Peptide Inhibitor of SARS-CoV-2 Targeting its Entry into the Host Cells.
32551560 2020. Discovery of Aptamers Targeting Receptor-Binding Domain of the SARS-CoV-2 Spike Glycoprotein.
32547694 2020. Blocking Coronavirus 19 Infection via the SARS-CoV-2 Spike Protein: Initial Steps.
32593613 2020. Testing of natural products in clinical trials targeting the SARS-CoV-2 (Covid-19) Viral Spike Protein-Angiotensin Converting Enzyme-2 (ACE2) interaction.
32540428 2020. Eltrombopag is a potential target for drug intervention in SARS-CoV-2 spike protein.
32552462 2020. Identification of bioactive compounds from Glycyrrhiza glabra as possible inhibitor of SARS-CoV-2 spike glycoprotein and non-structural protein-15: a pharmacoinformatics study.
| 32565126 2020. Targeting the SARS-CoV-2 spike glycoprotein prefusion conformation: virtual screening and molecular dynamics simulations applied to the identification of potential fusion inhibitors.
|
